PCRX - Pacira BioSciences provides update on July product sales

• Pacira BioSciences ( NASDAQ: PCRX ) reported Wednesday its preliminary product sales of $50.2M for July 2022, almost flat on year-on-year basis.
• It includes: EXPAREL net product sales, $40.9M; ZILRETTA sales, $8.2M; and iovera° net product sales, $1.1M.
• The company began recognizing sales of ZILRETTA in November 2021 after completing its acquisition of Flexion Therapeutics.
• "We are pleased to report continued EXPAREL growth despite lingering market disruptions. This solid performance underscores expanding adoption as the market continues to recognize the significant advantages of EXPAREL-based opioid-sparing approaches for postsurgical pain.....In addition, the market feedback around our Generation-2 iovera° device continues to be positive and we remain confident the product will return to more robust growth as the year progresses," noted Dave Stack, chairman and chief executive officer of Pacira BioSciences.
• "On the clinical front, we are working diligently to advance a pipeline of new growth opportunities with top line results for our two Phase 3 studies of EXPAREL as a lower extremity nerve block on track for the third and fourth quarters," added Stack.
• Earlier: Pacira BioSciences Non-GAAP EPS of $0.51 misses by $0.34, revenue of $169.41M in-line

For further details see: